Previous post
A Phase 1/2a, Multicenter, Open-Label, First-in-Human Study of DB-1311 in Advanced/Metastatic Solid Tumors
Next post
A First-In-Human Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Locally Advanced or Metastatic Solid Tumors including NSCLC with MET Alterations